Abzena unveils location for its latest biologics GMP site
Sanford, NC, facility will be its sixth globally
Three months removed from its original announcement, Abzena, a partner research organization (PRO) that specializes in the development and manufacture of complex biologics, has announced that its new GMP (good manufacturing practice) manufacturing facility will be in Sanford, NC. This marks Abzena’s sixth site, and manufacturing will begin mid-2022, the company says.
The new facility, which will be dedicated to cGMP (current good manufacturing practice) manufacturing capacity for mammalian biologics, is expected to cost over $200 million, and will produce approximately 325 jobs for Sanford.
The design of the facility has been enhanced for Phase III and commercial manufacturing of biologics. A phased approach to construction will initially allow four modular suites. Each suite will include up to two 2000L bioreactors. After the initial phase, two more 2000L suites will be added. Additionally, the site will be equipped to handle existing and new advances in manufacturing, such as continuous manufacturing and perfusion.
Strategic Trends in Pharmaceutical Manufacturing for Industry Leaders
March 10th 2025This link in the pharma supply chain is undergoing a major transformation propelled by technological advancements, regulatory changes, and evolving market dynamics, requiring industry leaders to adopt innovative strategies in order to remain competitive.
